[Form 4] UiPath, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Psyence Biomedical Ltd. (PBM) filed Form 20-F/A (Amendment No. 1) for FY ended 31 Mar 2025. The sole purpose is to add the management report on internal control over financial reporting (ICFR) that was inadvertently omitted from the original 25 Jun 2025 filing. No other sections of the annual report have been revised.

Key points:

• Management, including the CEO and CFO, evaluated ICFR and concluded controls were effective as of 31 Mar 2025.
• No material changes in ICFR occurred during the fiscal year.
• The company is a non-accelerated filer & emerging growth company; therefore, an external auditor attestation of ICFR is not required.
• Outstanding common shares at 31 Mar 2025: 568,021.
• Exhibits 12.1 and 12.2 contain re-executed Sarbanes-Oxley §302 certifications; various Inline XBRL files are also included.

The amendment does not affect previously reported financial statements or operational results and should be read in conjunction with the original Form 20-F.

Positive

• Management affirms effective disclosure controls and ICFR, suggesting reliable financial reporting.
• Certifications re-filed under SOX §302, closing a compliance gap without altering prior results.

Negative

• Need for an amendment highlights earlier oversight in governance processes.
• No external auditor ICFR attestation, though permissible, may offer less assurance to some investors.

Insights

Financial Reporting Analyst

TL;DR: Amendment adds missing ICFR report; controls deemed effective—minor procedural fix, limited investor impact.

The filing corrects an administrative oversight by supplying Item 15(b) disclosures. Management’s effective-control conclusion reduces concerns about misstatement risk, and unchanged ICFR indicates stable governance. Because no financial data or guidance is altered, valuation assumptions remain intact. The absence of auditor attestation is normal for a non-accelerated filer. Overall impact is neutral; investors gain comfort that compliance gap is closed without restatements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Dines Daniel

(Last) (First) (Middle)

C/O UIPATH, INC., ONE VANDERBILT AVENUE

60TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UiPath, Inc. [ PATH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/25/2025		S		45,000(1)	D	$12.2478(2)	4,743,376	I	See Footnote(3)
Class A Common Stock								24,918,585	D
Class A Common Stock								240,000	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold in compliance with a qualified selling plan adopted by the Reporting Person pursuant to Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.

2. The range of prices for the transactions reported was from $12.1800 to $12.3200. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.

3. The shares are held by Ice Vulcan Holding Limited. IceVulcan Investments Ltd. is the sole shareholder of Ice Vulcan Holding Limited, and Mr. Dines is the sole shareholder of IceVulcan Investments Ltd. Mr. Dines retains sole voting and investment power with respect to the shares of Class A Common Stock and Class B Common Stock held by Ice Vulcan Holding Limited.

Remarks:

	/s/ Brad Brubaker, Attorney-in-Fact	07/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Psyence Biomedical (PBM) file Form 20-F/A?

The amendment solely adds management’s report on internal control over financial reporting that was omitted from the original filing.

Did the amendment change PBM’s financial statements or guidance?

No. The filing states it does not update or modify the financial data disclosed on 25 Jun 2025.

What was management’s conclusion about PBM’s internal controls?

Management concluded PBM’s disclosure controls and ICFR were effective as of 31 Mar 2025.

Is an external auditor attestation of ICFR included?

No. As a non-accelerated filer, PBM is not required to obtain an auditor attestation report.

How many PBM shares were outstanding at fiscal year-end?

The filing reports 568,021 common shares outstanding as of 31 Mar 2025.

What are PBM’s trading symbols and exchange?

Common shares trade on Nasdaq under PBM; warrants trade under PBMWW.